カテゴリ： GlobalData, 企業調査, 南アフリカ

Aspen Pharmacare Holdings Ltd (APN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Aspen Pharmacare Holdings Ltd (APN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013431
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：南アフリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company also manufactures infant nutritionals and consumer healthcare products in selected territories. Its manufacturing capabilities cover a range of product-types including oral solid dose, semi-solids, liquids, steriles, biological, active pharmaceutical ingredients (APIs) and infant nutritionals. The company has presence across Sub-Saharan Africa, Latin America, South East Asia, Eastern Europe, Western Europe and the Commonwealth of Independent States. Aspen is headquartered in Durban, South Africa.

Aspen Pharmacare Holdings Ltd (APN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare to Acquire Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 25
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 28
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 30
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 31
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 33
Aspen Pharmacare Acquires Pharma Division Of Sigma Pharma 35
Partnerships 37
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 37
AstraZeneca Enters into Co-Marketing Agreement with Aspen 38
ANI Pharma Enters into Distribution Agreement with Aspen 39
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 40
Navamedic Amends Distribution Agreement With Aspen Pharma 41
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 42
Licensing Agreements 43
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 43
Aspen Pharma Enters into Licensing Agreement with Starpharma 44
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 45
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 46
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 47
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 48
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 49
Equity Offering 50
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 50
Asset Transactions 52
Endo International Acquires Portfolio of Branded and Generic Products 52
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 53
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 54
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 55
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 56
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 57
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 58
Acquisition 59
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 59
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 60
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 62
Aspen Pharmacare Holdings Ltd – Key Competitors 63
Aspen Pharmacare Holdings Ltd – Key Employees 64
Aspen Pharmacare Holdings Ltd – Locations And Subsidiaries 65
Head Office 65
Other Locations & Subsidiaries 65
Joint Venture 67
Recent Developments 68
Financial Announcements 68
Sep 14, 2017: Aspen increases revenue by 16% to R41.2 billion 68
Mar 09, 2017: Aspen: Unaudited interim financial results for the six months ended 31 December 2016 71
Sep 14, 2016: Aspens comparable revenue increases by 12% to R35.4 billion 74
Mar 03, 2016: Aspen’s profit after tax increases by 35% 76
Legal and Regulatory 79
Jun 13, 2017: Aspen: South African Competition Commission Announcement 79
May 15, 2017: Aspen: Opening of European Commission proceedings 80
Apr 24, 2017: Aspen’s response to the reported Competition Commission investigation 81
Government and Public Interest 82
May 15, 2017: Antitrust: Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines 82
Other Significant Developments 84
Mar 01, 2017: Aspen – Trading Statement 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Aspen Pharmacare Holdings Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Aspen Pharmacare Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 16
Aspen Japan Acquires Four Ethical Drug Brands from Kyowa Hakko Kirin 17
Aspen Pharmacare Acquires Anaesthesia Portfolio from GlaxoSmithKline 18
Aspen Global to Acquire Rights to Hydroxyprogesterone Caproate Injection form McGuff Pharma 19
Aspen Pharmacare Acquires Southern African Operations and Product Rights from Norgine 20
Aspen Pharmacare Plans to Acquire Infant Nutrition Business 21
Aspen Pharmacare to Acquire Rights to Mono-Embolex from Novartis 22
Aspen Pharma Acquires Infant Nutritional Businesses from Nestle for USD180 Million 23
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 25
Aspen Pharmacare Completes Acquisition of Thrombosis Brands And Manufacturing Facility from GlaxoSmithKline for USD1.13 Billion 28
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 30
Aspen Completes Acquisition Of Non-Core Australian Drugs From GlaxoSmithKline For US$257 Million 31
Aspen Pharmacare Completes Acquisition Of Non-Core OTC Brands From GlaxoSmithKline For US$263 Million 33
Aspen Pharmacare Acquires Pharma Division Of Sigma Pharma 35
Aspen Pharmacare Holdings to Enter into Research Agreement with Far Eastern Federal University 37
AstraZeneca Enters into Co-Marketing Agreement with Aspen 38
ANI Pharma Enters into Distribution Agreement with Aspen 39
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 40
Navamedic Amends Distribution Agreement With Aspen Pharma 41
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 42
Aspen Pharmacare Australia Enters into Licensing Agreement with Neurim Pharma 43
Aspen Pharma Enters into Licensing Agreement with Starpharma 44
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 45
TesoRx Pharma Enters into Licensing Agreement with Aspen Global 46
QRxPharma Exercises Option For Licensing Agreement With Aspen Pharma For Moxduo 47
QRxPharma Enters Into Licensing Agreement With Aspen Pharma For Moxduo 48
Tibotec Pharma Enters Into Licensing Agreement With Aspen Pharmacare For TMC278 49
Aspen Pharmacare Raises USD624 Million in Private Placement of Shares 50
Endo International Acquires Portfolio of Branded and Generic Products 52
Strides Arcolab Acquires Prescription Products from Aspen Global for USD92 million 53
Strides Arcolab Acquires Generic Pharma Business and Related Assets from Aspen Pharmacare for USD210 Million 54
Aspen Pharmacare to Divest Business Unit to Litha Pharma for USD134 Million 55
Mylan to Acquire Rights to Arixtra Injection from Aspen Global 56
Perrigo Acquires OTC Products From Aspen Global For US$51 Million 57
Lupin Acquires Worldwide Rights To Goanna Brand From Aspen Pharmacare 58
GlaxoSmithKline to Acquire 25% Stake in Aspen Japan 59
GlaxoSmithKline Completes Sale Of 6.19% Stake In Aspen Pharmacare For US$696.5 Million 60
Aspen Pharmacare Completes Acquisition Of Remaining 40% Stake In Shelys Africa For US$18.6 Million 62
Aspen Pharmacare Holdings Ltd, Key Competitors 63
Aspen Pharmacare Holdings Ltd, Key Employees 64
Aspen Pharmacare Holdings Ltd, Other Locations 65
Aspen Pharmacare Holdings Ltd, Subsidiaries 65
Aspen Pharmacare Holdings Ltd, Joint Venture 67

★海外企業調査レポート[Aspen Pharmacare Holdings Ltd (APN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Lockheed Martin Aeronautics Company：企業の戦略・SWOT・財務情報
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Banco Santander SA：戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Escalier Biosciences BV：製薬・医療：M&Aディール及び事業提携情報
    Summary Escalier Biosciences BV (Escalier Biosciences) is a biopharmaceutical company, which develops small molecule medicines for the treatment of autoimmune disorders. Its pipeline products include topical and oral RAR-related orphan receptor gamma inverse agonists. Inhibition of RAR-related orpha …
  • Aabar Investments：企業の戦略的SWOT分析
    Aabar Investments - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Putnam Investments LLC：企業の戦略的SWOT分析
    Putnam Investments LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • H. Lundbeck A/S：企業の戦略・SWOT・財務情報
    H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report Summary H. Lundbeck A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Siemens Heat Transfer Technology BV：企業の戦略的SWOT分析
    Siemens Heat Transfer Technology BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Central Electricity Generating Co：発電所・企業SWOT分析
    Central Electricity Generating Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Aviva Poland：企業の戦略・SWOT・財務情報
    Aviva Poland - Strategy, SWOT and Corporate Finance Report Summary Aviva Poland - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • NACHI-FUJIKOSHI CORP.：企業の戦略・SWOT・財務情報
    NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report Summary NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hartford HealthCare Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Hartford HealthCare Corp (HHC) is a healthcare service provider that offers clinical care, education and research services. The organization's services include behavioral and mental health, bone and joint care, cancer, cardiology and heart care, dermatology, diabetes and endocrinology, diges …
  • Tecpetrol SA：石油・ガス：M&Aディール及び事業提携情報
    Summary Tecpetrol SA (Tecpetrol), a subsidiary of Techint Group, is an oil and gas exploration and production company. The company acquires, explores, produces, transports and distributes oil and gas. It operates fields and blocks in Argentina, Venezuela, Bolivia, Ecuador, Mexico, Peru and Colombia. …
  • Charter Communications, Inc.：戦略・SWOT・企業財務分析
    Charter Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Charter Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Companhia Energetica de Sao Paulo (CESP6)：電力：M&Aディール及び事業提携情報
    Summary Companhia Energetica de Sao Paulo (CESP) is a state-owned integrated electric utility. It plans, constructs, and operates electric energy generation and commercialization systems. The company produces energy using hydro source. CESP owns power plants at Rio Paran, Rio Paraibuna, and Rio Jagu …
  • Swan Life Ltd.：企業の戦略・SWOT・財務情報
    Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report Summary Swan Life Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Day & Zimmermann Group, Inc.：企業の戦略・SWOT・財務分析
    Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Day & Zimmermann Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Purdue Pharma L.P.：企業の戦略・SWOT・財務情報
    Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report Summary Purdue Pharma L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • viDA Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary viDA Therapeutics Inc (viDA) is a biopharmaceutical company that discovers, develops and commercializes novel and targeted therapeutics for the treatment of autoimmune and age-related chronic inflammatory diseases. The company’s lead product candidate include VTI-1002, is in a topical formul …
  • UnitedHealth Group Incorporated：企業の戦略・SWOT・財務分析
    UnitedHealth Group Incorporated - Strategy, SWOT and Corporate Finance Report Summary UnitedHealth Group Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Imuraya Group Co., Ltd.：企業の戦略・SWOT・財務分析
    Imuraya Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Imuraya Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆